Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Cell Technology, Inc.
Cloning and cellular reprogramming intellectual property portfolio expanded
June 15th, 2005
A.C.T. Holdings, Inc., (ACTH.OB) and its wholly-owned subsidiary, Advanced Cell Technology, Inc., (collectively, ACT), announced that ACT has entered into two separate agreements to expand its portfolio of intellectual property in regard to somatic cell nuclear transfer (SCNT) and cellular reprogramming. In the first agreement, ACT acquired an option to exclusively license cloning patents from TranXenoGen, Inc., of Shrewsbury, Massachusetts. The patents include U.S. patents 5,480,772; 5,651,992; 5,773,217; 6,245,567; 6,753,457; and 6,878,546. This patent family includes granted claims related to somatic cell nuclear transfer and the use of oocytes and oocyte extracts to...
Source: Physician Law Weekly (2005-06-15)
|
